Antiplatelet Therapy After Implantation of Bioresorbable Vascular Scaffolds: A Review of the Literature, Practical Recommendations and Future Directions

The introduction of bioresorbable vascular scaffolds (BVS) for clinical use has raised a number of questions on whether current dual-antiplatelet therapy (DAPT) recommendations after drug-eluting stent (DES) implantation, mostly deriving from data on second-generation DES, are also applicable to this completely different technology. This article aims to review the technical shortcomings of BVS—the most extensively studied fully bioresorbable coronary stent—and its contemporary rates of scaffold thrombosis, with a focus on recommendations for DAPT duration.